ESPE Abstracts

As of 2022, the Ukraine Pediatric Diabetes Register (UPDR) contained children aged <18 years with DM1- 11014 (1 in 677), with DM2 – 51 (1 in 146274), with neonatal diabetes (ND) – 69 (1 in 108115), and 59 cases (1 in 126440) with MODY. Most studies focus on such parameters as HbA1c, acute complications and quality of life, whereas investigations of the frequency of chronic DM1 complications and glycemic control for internally displaced persons (IDP) have not been widely described. The UPDR was created in 2004. It contains all information about children with DM1 aged <18 years including HbA1c, the frequency of acute and chronic complications. We studied glycemic control, the frequency of acute and chronic complications and different treatment modalities including CSII (n=49) and MDII (n=337) for children aged 0-17 in the city of Dnipro. HbA1c and acute complications were also studied for IDP (n=30) who have been under our supervision for the last 9 months of war. The number of children in Dnipro in 2022y with DM1 was 354. Among DM1, there are 238 children aged 0-14 years old (34 of whom receive CSII), and 116 adolescents (15 of whom receive CSII). The level of HbA1c in for the patients in the city of Dnipro was 7.8±0.76%. The proportion of children who had ideal or optimal glycemic control (HbA1c <7.5%) was 33.9%. Our results showed the absence of a significant difference in the frequency of acute and chronic diabetes complications between CSII and MDII groups (P>0.05). However, a significant difference in the frequency of chronic complications and higher HbA1c was found in the 15-17 y.o. group vs 0-14 y.o. (P<0.05). The children who were treated with CSII had significantly lower HbA1c compared to MDII group (7.3±0.59% vs 7.9±0.7%, P<0.05) despite the similar duration of DM1 in these groups (P>0.05). However, this can be due to the more frequent CGMS use in CSII group (P<0.05). In IDP HbA1c and DKA1 were significantly higher compared to the Dnipro residents (8.2±1.1% vs 7.8±0.76% and 33,3% vs 5,9% respectively, P<0.05). Further treatment modalities should be studied in a pediatric cohort with DM1, especially in adolescents (15-17 y.o). The treatment of IDP can be a challenge for the health care system due to the stress of children and guardians, the inability to carry out sufficient self-monitoring and insulin therapy, and the lack of affordable and timely medical care.